Page 12 - Valuating News Today

NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative oral therapies for metabolic diseases, today announced that it has initiated a Phase 2 dose-finding

Intercept Pharmaceuticals, Inc. announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis , did not... | October 1, 2022

U.S. buyout funds KKR and CVC are evaluating buying stakes in Spanish hospital group Quironsalud from Germanys healthcare group Fresenius, news website El Confidencial reported on Friday citing... | September 30, 2022

Evaluation is critical to the EBRD's work. Learn how our Evaluation Department reviews projects and documents lessons learned.

The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - Horizon Therapeutics plc (Nasdaq:

Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field

Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBio The collaboration continues to build

-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022(NYSE American: SYN), a diversified

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical

BASEL (dpa-AFX) - Swiss drug major Novartis AG (NVS) announced Monday that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885) did not meet its primary endpoint